Skip to main content

Articles

Page 6 of 34

  1. Subjective cognitive decline (SCD) may serve as a symptomatic indicator for preclinical Alzheimer’s disease; however, SCD is a heterogeneous entity regarding clinical progression. We aimed to investigate wheth...

    Authors: Qian Chen, Futao Chen, Cong Long, Yajing Zhu, Yaoxian Jiang, Zhengyang Zhu, Jiaming Lu, Xin Zhang, Zuzana Nedelska, Jakub Hort and Bing Zhang
    Citation: Alzheimer's Research & Therapy 2023 15:86
  2. Authors: Bruno Dubois, Jesús López‑Arrieta, Stanley Lipschitz, Triantafyllos Doskas, Luiza Spiru, Svitlana Moroz, Olena Venger, Patrick Vermersch, Alain Moussy, Colin D. Mansfield, Olivier Hermine and Magda Tsolaki
    Citation: Alzheimer's Research & Therapy 2023 15:85

    The original article was published in Alzheimer's Research & Therapy 2023 15:39

  3. Although machine learning classifiers have been frequently used to detect Alzheimer’s disease (AD) based on structural brain MRI data, potential bias with respect to sex and age has not yet been addressed. Her...

    Authors: Malte Klingenberg, Didem Stark, Fabian Eitel, Céline Budding, Mohamad Habes and Kerstin Ritter
    Citation: Alzheimer's Research & Therapy 2023 15:84
  4. The development of drugs for Alzheimer’s disease (AD), which is related to the misfolding and aggregation of amyloid-β (Aβ), is high in demand due to the growing number of AD patients. In this study, we screen...

    Authors: Rina Nakamura, Motomi Konishi, Youichirou Higashi, Motoaki Saito and Toshifumi Akizawa
    Citation: Alzheimer's Research & Therapy 2023 15:83
  5. The medial parietal cortex is an early site of pathological protein deposition in Alzheimer’s disease (AD). Previous studies have identified different subregions within this area; however, these subregions are...

    Authors: Dániel Veréb, Mite Mijalkov, Yu-Wei Chang, Anna Canal-Garcia, Emiliano Gomez-Ruis, Anne Maass, Sylvia Villeneuve, Giovanni Volpe and Joana B. Pereira
    Citation: Alzheimer's Research & Therapy 2023 15:82
  6. During COVID-19 lockdown measures, memory clinic patients reported worries for faster cognitive decline, due to loss of structure and feelings of loneliness and depression. We aimed to investigate the impact o...

    Authors: Els D. Bakker, Stéphanie L. van der Pas, Marissa D. Zwan, Freek Gillissen, Femke H. Bouwman, Philip Scheltens, Wiesje M. van der Flier and Ingrid S. van Maurik
    Citation: Alzheimer's Research & Therapy 2023 15:81
  7. Crucial to the success of clinical trials targeting early Alzheimer’s disease (AD) is recruiting participants who are more likely to progress over the course of the trials. We hypothesize that a combination of...

    Authors: Long Xie, Sandhitsu R. Das, Laura E. M. Wisse, Ranjit Ittyerah, Robin de Flores, Leslie M. Shaw, Paul A. Yushkevich and David A. Wolk
    Citation: Alzheimer's Research & Therapy 2023 15:79

    The Correction to this article has been published in Alzheimer's Research & Therapy 2024 16:11

  8. Growing evidence has demonstrated that DNA methylation (DNAm) plays an important role in Alzheimer’s disease (AD) and that DNAm differences can be detected in the blood of AD subjects. Most studies have correl...

    Authors: Wei Zhang, Juan I. Young, Lissette Gomez, Michael A. Schmidt, David Lukacsovich, Achintya Varma, X. Steven Chen, Eden R. Martin and Lily Wang
    Citation: Alzheimer's Research & Therapy 2023 15:78
  9. Alzheimer’s disease (AD) is the 5th leading cause of death in people 65 years and older. The ATN classification reflects a biological definition of AD pathology with markers of Aβ deposition (A), pathologic ta...

    Authors: Mélina Régy, Aline Dugravot, Séverine Sabia, Elodie Bouaziz-Amar, Claire Paquet, Bernard Hanseeuw, Archana Singh-Manoux and Julien Dumurgier
    Citation: Alzheimer's Research & Therapy 2023 15:77
  10. Advances in pharmacological and non-pharmacological dementia interventions may mean future dementia prevention incorporates a combination of targeted screening and lifestyle modifications. Elucidating potentia...

    Authors: Nikki-Anne Wilson, Ruth Peters, Nicola T. Lautenschlager and Kaarin J. Anstey
    Citation: Alzheimer's Research & Therapy 2023 15:76
  11. Vascular dysfunction, including cerebral hypoperfusion, plays an important role in the pathogenesis and progression of Alzheimer’s disease (AD), independent of amyloid and tau pathology. We established an AD-r...

    Authors: Meng Meng, Fang Liu, Yilong Ma, Wen Qin, Lining Guo, Shichun Peng, Marc L. Gordon, Yue Wang and Nan Zhang
    Citation: Alzheimer's Research & Therapy 2023 15:75
  12. Plasma neurofilament light (NfL) is an indicator of neurodegeneration and/or neuroaxonal injury in persons with Alzheimer’s disease (AD) and a wide range of other neurological disorders. Here, we characterized...

    Authors: Michael Malek-Ahmadi, Yi Su, Valentina Ghisays, Ji Luo, Vivek Devadas, Yinghua Chen, Wendy Lee, Hillary Protas, Kewei Chen, Henrik Zetterberg, Kaj Blennow, Richard J. Caselli and Eric M. Reiman
    Citation: Alzheimer's Research & Therapy 2023 15:74
  13. In the context of the development of pharmaceutical interventions, expectations and experiences of participants are essential. Their insights may be particularly helpful to address the challenges of recruiting...

    Authors: Lois Ottenhoff, Everard G. B. Vijverberg, Leonie N. C. Visser, Merike Verijp, Niels D. Prins, Wiesje M. Van der Flier and Sietske A. M. Sikkes
    Citation: Alzheimer's Research & Therapy 2023 15:72
  14. Neuroinflammation, characterized by increased reactivity of microglia and astrocytes in the brain, is known to be present at various stages of the Alzheimer’s disease (AD) continuum. However, its presence and rel...

    Authors: Anniina Snellman, Laura L. Ekblad, Jouni Tuisku, Mikko Koivumäki, Nicholas J. Ashton, Juan Lantero-Rodriguez, Thomas K. Karikari, Semi Helin, Marco Bucci, Eliisa Löyttyniemi, Riitta Parkkola, Mira Karrasch, Michael Schöll, Henrik Zetterberg, Kaj Blennow and Juha O. Rinne
    Citation: Alzheimer's Research & Therapy 2023 15:71
  15. There is a need for a reliable, easy-to-use, widely available, and validated tool for timely cognitive impairment identification. We created a computerized cognitive screening tool (Santé-Cerveau digital tool ...

    Authors: Constance Lesoil, Stéphanie Bombois, Octave Guinebretiere, Marion Houot, Mahsa Bahrami, Marcel Levy, Rémy Genthon, Frédérique Bozon, Heidy Jean-Marie, Stéphane Epelbaum, Pierre Foulon, Nicolas Villain and Bruno Dubois
    Citation: Alzheimer's Research & Therapy 2023 15:70
  16. Previous studies have suggested a correlation between elevated levels of β2-microglobulin (B2M) and cognitive impairment. However, the existing evidence is insufficient to establish a conclusive relationship. Thi...

    Authors: Yi-Ming Huang, Ya-Hui Ma, Pei-Yang Gao, Zhi-Bo Wang, Liang-Yu Huang, Jia-Hui Hou, Lan Tan and Jin-Tai Yu
    Citation: Alzheimer's Research & Therapy 2023 15:69
  17. A growing body of evidence shows differences in the prevalence of cardiometabolic syndrome (CMS) and dementia based on gender and ethnicity. However, there is a paucity of information about ethnic- and gender-...

    Authors: Sung Hoon Kang, Mengting Liu, Gilsoon Park, Sharon Y. Kim, Hyejoo Lee, William Matloff, Lu Zhao, Heejin Yoo, Jun Pyo Kim, Hyemin Jang, Hee Jin Kim, Neda Jahanshad, Kyumgmi Oh, Seong-Beom Koh, Duk L. Na, John Gallacher…
    Citation: Alzheimer's Research & Therapy 2023 15:68
  18. Individuals from minority ethnic groups in the UK are thought to be at higher risk of developing dementia while facing additional barriers to receiving timely care. However, few studies in the UK have examined...

    Authors: Melissa Co, Christoph Mueller, Rosie Mayston, Jayati Das-Munshi and Matthew Prina
    Citation: Alzheimer's Research & Therapy 2023 15:67
  19. Both Alzheimer’s disease (AD) genetic risk factors and indices of cognitive reserve (CR) influence risk of cognitive decline, but it remains unclear whether they interact. This study examined whether a CR inde...

    Authors: Corinne Pettigrew, Jurijs Nazarovs, Anja Soldan, Vikas Singh, Jiangxia Wang, Timothy Hohman, Logan Dumitrescu, Julia Libby, Brian Kunkle, Alden L. Gross, Sterling Johnson, Qiongshi Lu, Corinne Engelman, Colin L. Masters, Paul Maruff, Simon M. Laws…
    Citation: Alzheimer's Research & Therapy 2023 15:66
  20. The use of music interventions as a non-pharmacological therapy to improve cognitive and behavioral symptoms in Alzheimer’s disease (AD) patients has gained popularity in recent years, but the evidence for the...

    Authors: Malak Bleibel, Ali El Cheikh, Najwane Said Sadier and Linda Abou-Abbas
    Citation: Alzheimer's Research & Therapy 2023 15:65
  21. Aβ42/Aβ40 ratios in cerebrospinal fluid (CSF) and blood are reduced in preclinical Alzheimer’s disease (AD), but their temporal and correlative relationship with cerebral Aβ pathology at this early disease sta...

    Authors: Emelie Andersson, Nina Schultz, Takashi Saito, Takaomi C. Saido, Kaj Blennow, Gunnar K. Gouras, Henrik Zetterberg and Oskar Hansson
    Citation: Alzheimer's Research & Therapy 2023 15:64
  22. Authors: Francesca Conca, Valentina Esposito, Francesco Rundo, Davide Quaranta, Cristina Muscio, Rosa Manenti, Giulia Caruso, Ugo Lucca, Alessia Antonella Galbussera, Sonia Di Tella, Francesca Baglio, Federica L’Abbate, Elisa Canu, Valentina Catania, Massimo Filippi, Giulia Mattavelli…
    Citation: Alzheimer's Research & Therapy 2023 15:63

    The original article was published in Alzheimer's Research & Therapy 2022 14:113

  23. Loss of synaptic functionality has been recently identified as an early-stage indicator of neurological diseases. Consequently, monitoring changes in synaptic protein levels may be relevant for observing disea...

    Authors: Shreyasee Das, Julie Goossens, Dirk Jacobs, Nele Dewit, Yolande A. L. Pijnenburg, Sjors G. J. G. In ‘t Veld, Charlotte E. Teunissen and Eugeen Vanmechelen
    Citation: Alzheimer's Research & Therapy 2023 15:62
  24. Connectome mapping may reveal new treatment targets for patients with neurological and psychiatric diseases. However, the long-term delayed recall based-network with structural and functional connectome is sti...

    Authors: Jie Ma, Mou-Xiong Zheng, Jia-Jia Wu, Xiang-Xin Xing, Yun-Ting Xiang, Dong Wei, Xin Xue, Han Zhang, Xu-Yun Hua, Qi-Hao Guo and Jian-Guang Xu
    Citation: Alzheimer's Research & Therapy 2023 15:61
  25. Alzheimer’s disease (AD) is a major global health crisis in need of more effective therapies. However, difficult choices to optimize value-based care will need to be made. While identifying preferred therapeut...

    Authors: George Dranitsaris, Quanwu Zhang, Lin Mu, Christopher Weyrer, Erik Drysdale, Peter Neumann, Alireza Atri and Amir Abbas Tahami Monfared
    Citation: Alzheimer's Research & Therapy 2023 15:60
  26. Frontotemporal lobar degeneration (FTLD) is characterized pathologically by neuronal and glial inclusions of hyperphosphorylated tau or by neuronal cytoplasmic inclusions of TDP43. This study aimed at decipher...

    Authors: Claire Bridel, Juami H. M. van Gils, Suzanne S. M. Miedema, Jeroen J. M. Hoozemans, Yolande A. L. Pijnenburg, August B. Smit, Annemieke J. M. Rozemuller, Sanne Abeln and Charlotte E. Teunissen
    Citation: Alzheimer's Research & Therapy 2023 15:59
  27. Cortical and subcortical microstructural modifications are critical to understanding the pathogenic changes in frontotemporal lobar degeneration (FTLD) subtypes. In this study, we investigated cortical and sub...

    Authors: Wencai Ding, Peng Ren, Liye Yi, Yao Si, Fan Yang, Zhipeng Li, Hongbo Bao, Shi Yan, Xinyu Zhang, Siyang Li, Xia Liang and Lifen Yao
    Citation: Alzheimer's Research & Therapy 2023 15:58
  28. Midlife hypertension has been recognized as a modifiable risk factor for dementia, but association between blood pressure (BP) in late life and dementia has been inconclusive. In addition, few studies have inv...

    Authors: Mi Hee Cho, Kyungdo Han, Seungwoo Lee, Su-Min Jeong, Jung Eun Yoo, SangYun Kim, Jinkook Lee, Sohyun Chun and Dong Wook Shin
    Citation: Alzheimer's Research & Therapy 2023 15:56
  29. Insulin resistance (IR) and type 2 diabetes have been found to increase the risk for Alzheimer’s clinical syndrome in epidemiologic studies but have not been associated with tau tangles in neuropathological re...

    Authors: Gilda E. Ennis, Tobey J. Betthauser, Rebecca Langhough Koscik, Nathaniel A. Chin, Bradley T. Christian, Sanjay Asthana, Sterling C. Johnson and Barbara B. Bendlin
    Citation: Alzheimer's Research & Therapy 2023 15:55
  30. The relationship between biomarkers of metabolic syndrome and insulin resistance, plasma triglyceride/HDL cholesterol (TG/HDL-C) ratio, on the rate of cognitive decline in mild cognitive impairment (MCI) and d...

    Authors: Jagan A. Pillai, James Bena, Lynn Bekris, Nandan Kodur, Takhar Kasumov, James B. Leverenz and Sangeeta R. Kashyap
    Citation: Alzheimer's Research & Therapy 2023 15:54
  31. Alzheimer’s disease (AD) and osteoporosis are two distinct diseases but often occur in the same patient. Their relationship remains poorly understood. Studies using Tg2576 AD animal model demonstrate bone defi...

    Authors: Li Chen, Lei Xiong, Lingling Yao, Jinxiu Pan, Emily Arzola, Xiaojuan Zhu, Lin Mei and Wen-Cheng Xiong
    Citation: Alzheimer's Research & Therapy 2023 15:53
  32. A key histopathological hallmark of Alzheimer’s disease (AD) is the presence of neurofibrillary tangles of aggregated microtubule-associated protein tau in neurons. Anle138b is a small molecule which has previ...

    Authors: Layla Hosseini-Gerami, Elena Ficulle, Neil Humphryes-Kirilov, David C. Airey, James Scherschel, Sarubini Kananathan, Brian J. Eastwood, Suchira Bose, David A. Collier, Emma Laing, David Evans, Howard Broughton and Andreas Bender
    Citation: Alzheimer's Research & Therapy 2023 15:52
  33. CSF-soluble platelet-derived growth factor receptor beta (sPDGFRβ) is closely associated with pericyte damage. However, the changes in CSF sPDGFRβ levels and their role in bloodbrain barrier (BBB) leakage at dif...

    Authors: Xinyi Lv, Mengguo Zhang, Zhaozhao Cheng, Qiong Wang, Peng Wang, Qiang Xie, Ming Ni, Yong Shen, Qiqiang Tang and Feng Gao
    Citation: Alzheimer's Research & Therapy 2023 15:51
  34. The NIA-AA proposed amyloid-tau-neurodegeneration (ATN) as a classification system for AD biomarkers. The amyloid cascade hypothesis (ACH) implies a sequence across ATN groups that patients might undergo durin...

    Authors: Nils Heinzinger, Anne Maass, David Berron, Renat Yakupov, Oliver Peters, Jochen Fiebach, Kersten Villringer, Lukas Preis, Josef Priller, Eike Jacob Spruth, Slawek Altenstein, Anja Schneider, Klaus Fliessbach, Jens Wiltfang, Claudia Bartels, Frank Jessen…
    Citation: Alzheimer's Research & Therapy 2023 15:50
  35. Disease-modifying agents to counteract cognitive impairment in older age remain elusive. Hence, identifying modifiable factors promoting resilience, as the capacity of the brain to maintain cognition and funct...

    Authors: Kilian Abellaneda-Pérez, Gabriele Cattaneo, María Cabello-Toscano, Javier Solana-Sánchez, Lídia Mulet-Pons, Lídia Vaqué-Alcázar, Ruben Perellón-Alfonso, Cristina Solé-Padullés, Núria Bargalló, Josep M. Tormos, Alvaro Pascual-Leone and David Bartrés-Faz
    Citation: Alzheimer's Research & Therapy 2023 15:49
  36. Cerebrospinal fluid (CSF) p-tau235 is a novel biomarker highly specific of Alzheimer’s disease (AD). However, CSF p-tau235 has only been studied in well-characterized research cohorts, which do not fully refle...

    Authors: Juan Lantero-Rodriguez, Agathe Vrillon, Aida Fernández-Lebrero, Paula Ortiz-Romero, Anniina Snellman, Laia Montoliu-Gaya, Wagner S. Brum, Emmanuel Cognat, Julien Dumurgier, Albert Puig-Pijoan, Irene Navalpotro-Gómez, Greta García-Escobar, Thomas K. Karikari, Eugeen Vanmechelen, Nicholas J. Ashton, Henrik Zetterberg…
    Citation: Alzheimer's Research & Therapy 2023 15:48
  37. Although a variety of brain lesions may contribute to the pathological assessment of dementia, the relationship of these lesions to dementia, how they interact and how to quantify them remains uncertain. Syste...

    Authors: Mohammed D. Rajab, Emmanuel Jammeh, Teruka Taketa, Carol Brayne, Fiona E. Matthews, Li Su, Paul G. Ince, Stephen B. Wharton and Dennis Wang
    Citation: Alzheimer's Research & Therapy 2023 15:47
  38. Restless leg syndrome (RLS) is associated with poor sleep quality, depression or anxiety, poor dietary patterns, microvasculopathy, and hypoxia, all of which are known risk factors for dementia. However, the r...

    Authors: Keun You Kim, Eun Hwa Kim, Myeongjee Lee, Junghee Ha, Inkyung Jung and Eosu Kim
    Citation: Alzheimer's Research & Therapy 2023 15:46
  39. There is a critical need for novel primary endpoints designed to detect early and subtle changes in cognition in clinical trials targeting the asymptomatic (preclinical) phase of Alzheimer’s disease (AD). The ...

    Authors: Angelika Caputo, Amy Racine, Ines Paule, Pierre N. Tariot, Jessica B. Langbaum, Neva Coello, Marie-Emmanuelle Riviere, J. Michael Ryan, Cristina Lopez Lopez and Ana Graf
    Citation: Alzheimer's Research & Therapy 2023 15:45
  40. Neurofilament light (NfL) and neurogranin (Ng) are promising candidate AD biomarkers, reflecting axonal and synaptic damage, respectively. Since there is a need to understand the synaptic and axonal damage in ...

    Authors: Maya Arvidsson Rådestig, Ingmar Skoog, Tobias Skillbäck, Henrik Zetterberg, Jürgen Kern, Anna Zettergren, Ulf Andreasson, Hanna Wetterberg, Silke Kern and Kaj Blennow
    Citation: Alzheimer's Research & Therapy 2023 15:44
  41. In preclinical Alzheimer’s disease, it is unclear why some individuals with amyloid pathologic change are asymptomatic (stage 1), whereas others experience subjective cognitive decline (SCD, stage 2). Here, we...

    Authors: Zerrin Yildirim, Firuze Delen, David Berron, Hannah Baumeister, Gabriel Ziegler, Hartmut Schütze, Wenzel Glanz, Laura Dobisch, Oliver Peters, Silka Dawn Freiesleben, Luisa-Sophie Schneider, Josef Priller, Eike Jakob Spruth, Anja Schneider, Klaus Fliessbach, Jens Wiltfang…
    Citation: Alzheimer's Research & Therapy 2023 15:43
  42. Amyloid deposition is a primary predictor of Alzheimer’s disease (AD) and related neurodegenerative disorders. Retinal changes involving the structure and function of the ganglion cell layer are increasingly d...

    Authors: Daniel C. Javitt, Antigona Martinez, Pejman Sehatpour, Anna Beloborodova, Christian Habeck, Yunglin Gazes, Dalton Bermudez, Qolamreza R. Razlighi, D. P. Devanand and Yaakov Stern
    Citation: Alzheimer's Research & Therapy 2023 15:42
  43. There is an increasing interest in utilizing tau PET to identify patients early in Alzheimer’s disease (AD). In this work, a temporal lobe composite () volume of interest (VOI) was evaluated in a longitudinal f...

    Authors: Vikas Kotari, Sudeepti Southekal, Michael Navitsky, Ian A. Kennedy, Ming Lu, Amanda Morris, Jennifer Ann Zimmer, Adam S. Fleisher, Mark A. Mintun, Michael D. Devous Sr and Michael J. Pontecorvo
    Citation: Alzheimer's Research & Therapy 2023 15:41
  44. Neuropsychology and imaging changes have been reported in the preclinical stage of familial Alzheimer’s disease (FAD). This study investigated the effects of APOEε4 and known pathogenic gene mutation on different...

    Authors: Meina Quan, Qi Wang, Wei Qin, Wei Wang, Fangyu Li, Tan Zhao, Tingting Li, Qiongqiong Qiu, Shuman Cao, Shiyuan Wang, Yan Wang, Hongmei Jin, Aihong Zhou, Jiliang Fang, Longfei Jia and Jianping Jia
    Citation: Alzheimer's Research & Therapy 2023 15:40
  45. Masitinib is an orally administered tyrosine kinase inhibitor that targets activated cells of the neuroimmune system (mast cells and microglia). Study AB09004 evaluated masitinib as an adjunct to cholinesteras...

    Authors: Bruno Dubois, Jesús López-Arrieta, Stanley Lipschitz, Triantafyllos Doskas, Luiza Spiru, Svitlana Moroz, Olena Venger, Patrick Vermersch, Alain Moussy, Colin D. Mansfield, Olivier Hermine and Magda Tsolaki
    Citation: Alzheimer's Research & Therapy 2023 15:39

    The Correction to this article has been published in Alzheimer's Research & Therapy 2023 15:85

  46. Identifying blood-based signatures of brain health and preclinical pathology may offer insights into early disease mechanisms and highlight avenues for intervention. Here, we systematically profiled associatio...

    Authors: Rebecca E. Green, Jodie Lord, Marzia A. Scelsi, Jin Xu, Andrew Wong, Sarah Naomi-James, Alex Handy, Lachlan Gilchrist, Dylan M. Williams, Thomas D. Parker, Christopher A. Lane, Ian B. Malone, David M. Cash, Carole H. Sudre, William Coath, David L. Thomas…
    Citation: Alzheimer's Research & Therapy 2023 15:38
  47. Subtypes and patterns are defined using tau-PET (tau pathology) and structural MRI (atrophy) in Alzheimer’s disease (AD). However, the relationship between tau pathology and atrophy across these subtypes/patte...

    Authors: Rosaleena Mohanty, Daniel Ferreira, Agneta Nordberg and Eric Westman
    Citation: Alzheimer's Research & Therapy 2023 15:37

    The Correction to this article has been published in Alzheimer's Research & Therapy 2023 15:80